In particular, a direct involvement of ERK5 in hepatocellular carcinoma (HCC) has been established, where aberrant activation of MEK5/ERK5 signaling and ERK5/MAPK7 gene amplification have been reported and correlated with tumor progression and poor prognosis [23–25]. The gene discussed is MAP2K5; the disease is hepatocellular carcinoma.